ArticleBMJ neurology open2025
Patient and physician perceptions of the burden of tardive dyskinesia: an international survey.
Article in BMJ neurology open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Tardive blepharospasm.Journal of neurology · 2026Article
- Hyperoside Stabilizes Redox-Mitochondrial-Inflammatory Networks in a Haloperidol-Induced Tardive Dyskinesia-Like Model.Life (Basel, Switzerland) · 2026Article
- Living with tardive dyskinesia: understanding the patient experience.CNS spectrums · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tardive dyskinesia (TD) negatively affects overall quality of life (QoL) and day-to-day activities, and perceptions of these effects and their impact may vary between cultures and societies, or providers and patients. Physicians' discernments of this burden could improve efforts to detect, diagnose and treat TD. This study assessed TD impact from both patients' and physicians' perspectives in multiple countries. Methods: Patients who self-reported a physician diagnosis of TD and schizophrenia, schizoaffective disorder, bipolar disorder or major depressive disorder exhibiting 'extra, irregular movements' and physicians (neurologists or psychiatrists) who treated ≥3 patients with TD in the prior 2 years participated in individual 20-minute online surveys. Participating physicians and patients were not linked. Results: Patients (N=435) and physicians (N=340) were recruited from Australia, Brazil, China, South Korea and Israel. Most patients (84.8%) and physicians (87.6%) reported a moderate/high or moderate to very strong impact of TD symptoms on QoL. Patients and physicians noted substantial negative impacts of TD on patients' daily lives, emotional and psychological states, and social activities. Many patients reported that TD often/always affected their treatment compliance for their underlying psychiatric condition (28.7%); that TD worsened their underlying psychiatric condition (24.8%), or that they developed other psychiatric conditions (46.9%); most physicians similarly perceived a moderate/very strong impact of TD in these areas (75.3%, 70.9% and 77.6%, respectively). Conclusions: Patients and physicians across participating countries agreed that TD substantially impacts patient QoL and can undermine psychiatric stability by worsening underlying psychiatric conditions and treatment adherence. Also, physicians saw the physical and emotional/psychological/social effects of TD as being almost equally impactful, whereas patients generally reported a greater impact of emotional/psychological/social effects than physical effects. The differences between the levels of importance that patients and physicians assigned to these areas of TD impact highlight the need for more thorough communication between them.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.